News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Long-acting HIV treatment news

Show

From To
HIV treatment
Top 10 HIV Clinical Developments of 2017

By David Alain Wohl, M.D., professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC).

Published
19 November 2017
From
The Body Pro
Resistance
Long-acting monoclonal antibody effective against multidrug-resistant HIV

Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited

Published
12 October 2017
By
Liz Highleyman
New and experimental HIV treatments
Promising HIV Treatments in Late-Stage Clinical Development

The following monotherapies and combination regimens are in late-stage clinical development or FDA review.

Published
02 October 2017
From
P&T Community
New and experimental HIV treatments
Long-acting NRTI shows promise for HIV treatment and PrEP

A single oral dose of MK-8591, a long-acting antiretroviral in a novel drug class, suppressed HIV for seven days in an early clinical trial, and the drug

Published
02 August 2017
By
Liz Highleyman
New and experimental HIV treatments
Long-acting cabotegravir + rilpivirine injection shows good results at 96 weeks

Two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, administered once every 4 or 8 weeks maintained viral suppression in about 90% of people who started therapy with an undetectable

Published
24 July 2017
By
Liz Highleyman
New and experimental HIV treatments
The 2017 Pipeline Report

Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
19 July 2017
From
Treatment Action Group
PrEP science
Long-acting Injectable Antiretrovirals for PrEP: Will the tail wag the drug?

A medicine you get only every two months to reduce your risk of acquiring HIV sounds like a great deal. And that could be an option in the future. But only if two big efficacy trials of long-acting injectable cabotegravir (CAB-LA) show that it is safe and effective.

Published
09 June 2017
From
AVAC
New and experimental HIV treatments
Several new candidates in HIV drug pipeline discussed at conference

This year's Conference on Retroviruses and Opportunistic Infections (CROI 2017), held last month in Seattle, included presentations on several new investigational antiretroviral drugs in development, reflecting a more

Published
15 March 2017
By
Liz Highleyman
New and experimental HIV treatments
Charlie Sheen Achieves Undetectable Viral Load With Weekly Injectable HIV Treatment

Actor Charlie Sheen revealed this month that he has achieved an undetectable viral load by taking PRO 140, an injectable HIV drug that's currently being studied. Sheen started taking PRO 140 as a study participant in a phase-3 clinical trial that is looking into the drug's safety and effectiveness in humans.

Published
08 December 2016
From
The Body
New and experimental HIV treatments
China to approve 1st long-acting injection to treat HIV/AIDS

China's national drug authority on Wednesday examined clinical research results on a domestically produced anti-HIV drug in its final phase prior to officially approving the drug. Once approved, the new-generation drug, named Albuvirtide for Injection, is expected to be the world's first long-acting injection for HIV treatment.

Published
25 November 2016
From
Global Times
← Prev1...23456...7Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.